Prime Medicine

Prime Medicine’s Q3 2025 report highlights advancements in its gene editing programs. IND/CTA filing for Wilson’s Disease is expected in H1 2026, with initial data in 2027. PM647 was nominated for AATD, targeting IND/CTA in mid-2026. Preclinical PM577 data will be presented at AASLD. The company reported a $50.6M net loss but holds $227.0M in cash, projected to fund operations into 2027. Matthew Hawryluk was appointed Chief Business Officer. A KOL event on WD strategy is scheduled for November 12, 2025.

Prime Medicine (PRME) announced a public offering of 38 million shares at $3.30 per share, expecting $125.4 million in gross proceeds. The Cystic Fibrosis Foundation will purchase 1.8 million shares without underwriter commissions. Underwriters have an option to purchase 5.7 million additional shares. The offering, managed by TD Cowen and BMO Capital Markets, is set to close around August 1, 2025. Proceeds will bolster Prime Medicine’s gene therapy pipeline advancement. The offering may cause dilution for existing shareholders.